CORTEF (hydrocortisone cypionate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Approved for dermatomyositis, temporal arteritis, polymyositis and 14 more indications. First approved in 1955.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
CORTEF (hydrocortisone cypionate) is an oral glucocorticoid suspension approved in 1955 for replacement therapy in adrenocortical deficiency and anti-inflammatory treatment across multiple organ systems. It treats conditions including systemic lupus erythematosus, rheumatoid arthritis, asthma, ulcerative colitis, and severe allergic reactions by modulating immune response and reducing inflammation.
Product approaching loss of exclusivity with modest Part D spending of $683K in 2023; brand team likely in maintenance/transition mode with limited headcount expansion.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Worked on CORTEF at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects
A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCORTEF generates zero linked job opportunities, reflecting its legacy status as a mature, low-commercial-priority product within Pfizer's portfolio. Career prospects on this brand are limited to field maintenance roles and do not offer growth trajectory typical of growth-stage or peak-revenue products.